Tandem Diabetes Care Files 8-K

TL;DR

Tandem Diabetes Care filed an 8-K, mostly financial docs. No major news.

AI Summary

On March 21, 2024, Tandem Diabetes Care, Inc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, with no specific material events or other significant business updates detailed in the provided text.

Why It Matters

This filing indicates Tandem Diabetes Care is submitting required financial statements and exhibits to the SEC, a routine but necessary part of public company compliance.

Risk Assessment

Risk Level: low — The filing appears to be a routine submission of financial statements and exhibits, not indicating any immediate business risks.

Key Players & Entities

• Tandem Diabetes Care, Inc. (company) — Registrant
• Delaware (jurisdiction) — State of incorporation
• 20-4327508 (tax_id) — I.R.S. Employer Identification No.
• 12400 High Bluff Drive (address) — Principal executive offices
• San Diego (city) — Principal executive offices
• California (state) — Principal executive offices
• 92130 (zip_code) — Principal executive offices
• 858-366-6900 (phone_number) — Registrant's telephone number
• March 21, 2024 (date) — Date of earliest event reported

FAQ

From the Filing

0001438133-24-000047.txt : 20240401 0001438133-24-000047.hdr.sgml : 20240401 20240401163336 ACCESSION NUMBER: 0001438133-24-000047 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20240321 ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240401 DATE AS OF CHANGE: 20240401 FILER: COMPANY DATA: COMPANY CONFORMED NAME: TANDEM DIABETES CARE INC CENTRAL INDEX KEY: 0001438133 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] ORGANIZATION NAME: 08 Industrial Applications and Services IRS NUMBER: 204327508 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-36189 FILM NUMBER: 24809968 BUSINESS ADDRESS: STREET 1: 12400 HIGH BLUFF DRIVE CITY: San Diego STATE: CA ZIP: 92130 BUSINESS PHONE: 858-366-6900 MAIL ADDRESS: STREET 1: 12400 HIGH BLUFF DRIVE CITY: San Diego STATE: CA ZIP: 92130 8-K 1 tndm-20240321.htm 8-K tndm-20240321 0001438133 FALSE 0001438133 2024-03-21 2024-03-21   UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ____________________________ FORM 8-K ____________________________ CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 21, 2024 ____________________________ Tandem Diabetes Care, Inc. (Exact name of registrant as specified in its charter) ____________________________ Delaware 001-36189 20-4327508 (State or other jurisdiction of incorporation) (Commission File Number) (I.R.S. Employer  Identification No.) 12400 High Bluff Drive 92130 San Diego California (Zip Code) (Address of principal executive offices) Registrant’s telephone number, including area code: ( 858 )  366-6900 N/A (Former name or former address, if changed since last report) ____________________________ Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐     Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐     Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐     Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐     Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of Each Class Trading Symbol Name of Each Exchange on Which Registered Common Stock, par value $0.001 per share TNDM NASDAQ Global Market Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter). Emerging growth company  ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐ ____________________________ Item 8.01 Other Events. On March 21, 2024, the U.S. Food and Drug Administration cleared our 510(k) application for our Tandem Mobi insulin pump with an expanded pediatric indication for use in individuals two years of age and older. Item 9.01 Financial Statements and Exhibits. (d)     Exhibits.   Number Description 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). 2 SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its beha